⏰ “This outbreak can still be brought under control, but the window for action is narrowing.” One month after the Ebola disease outbreak was declared in DRC, major gaps in surveillance, diagnosis, contact tracing and community engagement persist.

In San Pedro Sula, Honduras, we're improving access to sexual and reproductive health services for adolescents.  🎥 Diana Dáila, our medical activity manager in Honduras, tells us how her team provides this care.

Cancer is becoming one of the most serious health challenges in Papua New Guinea. Patients often come in late for care, and there is limited capacity for diagnosis and treatment. Our new cancer initiative in Morobe province is addressing gaps in care:

With no validated treatments or vaccines yet, and limited diagnostics for Bundibugyo virus disease, R&D and funding must embed transparent and enforceable conditions from the outset to guarantee timely, sustainable access to affordable medical tools for the most affected communities.

#Ebola outbreaks: There are currently no approved vaccines or treatments available for the #Bundibugyo virus. Our teams, along the Democratic Republic of Congo’s MOH are working to contain the spread of the disease and strengthen patient care: www.doctorswithoutborders.ca/democratic-r...

In eastern DRC, our teams are working to contain the spread of the Ebola disease outbreak and strengthen patient care, alongside the Ministry of Health. Learn about our response so far:

👋 Meet Nombuso Ntshalintshali, our laboratory manager at Sitsandziwe clinic in Eswatini! Her lab uses a ‘test and treat’ approach, giving fast, accurate results for sexually transmitted infections so that patients can get targeted medications that reduce the risk of antibiotic resistance.

“A more equitable system can begin today if governments choose to act on the commitments they have already made in the Pandemic Agreement.” MSF statement at #WHA79, delivered by Yuanqiong Hu, Head of Analysis, MSF Access. Read the full statement: msfaccess.org/open-ended-i...

🚨 Ebola in DRC Our teams are scaling up our response to the Ebola disease outbreak in DRC. How are we responding? What's different about this outbreak? Why are we concerned? Read the answers here ⬇️ 

🥁 We’re continuing our drumbeat call of analogue insulin pens for all at #WHA79. It’s time for countries & @who.int to end the double standard in diabetes care and include analogue insulin pens and glucose monitoring devices in all diabetes guidelines. msfaccess.org/follow-polit...

Why is this Ebola disease outbreak different? John Johnson, our medical lead for epidemic response, gave an interview to explain the Bundibugyo virus and its challenges:

“Immediately closing the devastating vaccination coverage gaps we’re seeing requires political will,” Dr Daniela Garone, MSF Read our call ahead of discussions on the progress towards reaching global immunisation goals #IA2030 at #WHA79. msfaccess.org/urgent-actio...

This week, we're right here at the World Health Assembly #WHA79, calling for countries to make sure global health policies for the coming years ensure everyone, everywhere has access to affordable medical products.

MSF representatives will address critical health issues at the World Health Assembly #WHA79 this week, calling for urgent action on: 🦠Antimicrobial resistance 🩺Noncommunicable diseases 😷Pandemic preparedness & response 💉Vaccines Read the statements: msfaccess.org/msf-statemen...

📢 This World Health Assembly #WHA79, we’re calling for countries, donors, and other global health stakeholders to urgently dismantle the barriers blocking access to lifesaving vaccination in conflict-affected settings by:

Did you know that the Pandemic Agreement, signed one year ago, is still on hold because of an annex? Enter the PABS* annex! * Pathogen Access and Benefit Sharing

In South Kivu, Democratic Republic of Congo, a new challenge is disrupting healthcare. Funding withdrawals are making vital care inaccessible, particularly for pregnant women and newborns. Read our latest press release here ⬇️

From five ways to improve vaccine access to outrage over pharma failing to address the barriers stopping people from accessing HIV prevention medication, explore our call for disease prevention not to be a privilege in our latest MSF Access newsletter: msfaccess.org/newsletter/f...

We are pleased to welcome Kris Torgeson as the incoming Executive Director of MSF Access.

Also discussed last week with @msfaccess.org on @sabcnews.bsky.social Channel Africa 🎧 omny.fm/shows/africa...

In 2024, half of the 14.3 million children who missed out on receiving any vaccination lived in countries affected by conflict, fragility, or humanitarian crises. It's time to close this gap through timely access to vaccines for all children, everywhere. #WorldImmunizationWeek

Neglected diseases are estimated to affect >1 billion people. However, there's limited attention and funding into vaccine research & development for these diseases. Safe & effective vaccines would be impactful in reducing the burden of neglected diseases. #WorldImmunisationWeek

Each year, over a quarter of a million children acquire chronic hepatitis B at birth, resulting in many premature deaths. If every newborn received hepatitis B birth dose – an affordable vaccine supported by Gavi – these deaths could be prevented. #WorldImmunizationWeek

Investing in innovations like vaccine Microarray Patches could help overcome barriers to reaching people in remote, conflict-affected, and fragile settings with vaccination. #WorldImmunisationWeek

Tuberculosis continues to kill more than 1 million people each year. A safe, effective, and affordable vaccine to protect adolescents and adults against #tuberculosis would be a significant step towards reducing global mortality due to TB. #WorldImmunizationWeek

This World Immunisation Week (24-30 April), we’ll be sharing five videos featuring MSF staff highlighting key pathways to reach more people with lifesaving vaccines. Stay tuned.

No more one-sided deals. As WHO talks reach a critical stage, MSF writes to the EU to ensure pathogen and data sharing comes with binding commitments to access to medical tools for people who need them most. msfaccess.org/open-letter-...

People in many countries with high HIV rates can’t access lenacapavir as prices remain too high and Gilead tightly controls its supply and production.

Gilead’s latest announcement on lenacapavir to provide injectable pre-exposure prophylaxis (PrEP) to up to one million more people in three years falls far short of what's needed to make a real dent in HIV transmission globally.

Gilead announcement does not address reasons people can’t access groundbreaking HIV prevention medicine www.doctorswithoutborders.org/latest/gilea...

Across Africa, funding constraints for research & development (R&D) are taking effect. In Feb 2026, we convened experts to discuss the now urgent need to build a more equitable and sustainable R&D ecosystem in Africa. Read our report 👉 msfaccess.org/shifting-glo...

Argentina has revoked key pharmaceutical patentability guidelines, a roll-back that could create and extend more monopolies, and, ultimately, delay or deny people’s access to affordable healthcare. healthpolicy-watch.news/argentina-ha...

🦠 The impact of antimicrobial resistance (#AMR) in conflict-affected settings is severe.    The full report brings together practitioner experiences and offers ways to address AMR in some of the most fragile contexts, with lessons relevant worldwide. 👉 msfaccess.org/antimicrobia...

New MSF analysis sheds light on how monoclonal antibodies can increase protection for people after exposure to Ebola. What’s needed now is more research and improved access to this promising treatment for healthcare workers and community members. revuemtsi.societe-mtsi.fr/index.php/bs...

Before the diagnosis, Hareem and Ahmad were often unwell. They had poor appetite, abdominal pain, irritability, and were becoming weak. Their mother had taken them to a nearby clinic where they were given medicines without proper diagnosis, but their condition did not improve.

The Head of the Paediatrics Department at Gujranwala Teaching Hospital (Pakistan), Dr Saima Umar, shares her experience of how WHO Treatment Decision Algorithms are helping diagnose children with #tuberculosis more effectively and the challenges doctors faced before their introduction.

Despite Gilead’s public claims that it can expand production of lenacapavir to meet needs, the company has refused requests from MSF to purchase a limited supply for use in our programs. Read our open letter to Gilead here: www.doctorswithoutborders.org/latest/preve...

NEW: US pharmaceutical corporation Gilead Sciences is refusing to sell groundbreaking HIV prevention drug to MSF.

“AMR in conflict or humanitarian settings is right there. It’s in front of us. We're already dealing with it.” Dr Kalyan Velivela, MSF health programme manager for South Sudan, Ethiopia, and Nigeria. Addressing AMR in humanitarian settings means acting on our shared experiences.

On #WorldTBDay, MSF urges governments and donors to put children at the heart of the global TB response. Sustained funding is needed to diagnose, treat, and prevent TB in children, who remain one of the most vulnerable groups.    msfaccess.org/msf-demands-...

Why half of the 1.2 million children with TB cannot access diagnosis and lifesaving treatment? Watch this video to learn more. #WorldTBDay     www.youtube.com/watch?v=6k6Y...

Drawing on MSF’s frontline experience across emergencies, we’re calling on EU to progress towards a system that ensures fair and equitable benefit‑sharing in exchange for access to pathogens and genetic resources used in R&D, including clinical trials. msfaccess.org/msf-calls-eu...

In 2011, more than 3,000 people marched in India to oppose harmful provisions that could have been included in EU–India free trade agreement and threatened access to affordable medicines. Fifteen years later, after two decades of sustained advocacy, those were excluded from the final deal.

India-EU free trade agreement full text has been released and the intellectual property chapter: 👍Largely preserves India’s public health safeguards and doesn't go beyond @wto.org TRIPS agreement 🛑 BUT 🛑

In 2014, I visited eastern DRC, where @msf.org teams were treating sleeping sickness - the only available treatment was a drug so toxic it killed 1 in 20 patients. In 2026 I'm so proud that, thanks to @dndi.org, patients can be cured with a single dose of a groundbreaking new oral drug, acoziborole.

🚀 Huge news for people living with #sleepingsickness! Acoziborole, a one-day, single-dose oral treatment developed with Sanofi, has received a positive opinion from @ema.europa.eu for the treatment of the most common form of sleeping sickness. 👉 bit.ly/46ZFpEi

Thanks @madhupai.bsky.social for the spotlight on TB in Europe. Additionally, lack of access to treatment due to unavailability, high prices, and fragmented supply of TB medicines remains a major challenge. Critical DR-TB meds are exorbitantly priced in the region: some over 100x than in LMICs!

Read MSF’s recommendations for a strong WHO Pathogen Access and Benefit-Sharing (PABS) system calling for reliable, equitable and accountable access to vaccines, diagnostics and treatments developed from shared samples and data. msfaccess.org/ensuring-col...

👉 @msfbrasil.bsky.social is seeking to intervene in a Supreme Court case challenging Brazil’s new law on research, which limits the right of clinical trial participants to receive free access to medicines developed from the studies they joined.

MSF representatives addressed critical issues in fragile settings at the @who.int Executive Board #EB158 this week, calling for urgent action on: 🔹Antimicrobial resistance (AMR) 🔹Mental health 🔹Noncommunicable diseases (NCDs) 🔹Vaccines Read the statements: msfaccess.org/msf-statemen...